相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes
Lifei Wang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Mitra Zabihi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Emerging approaches to CDK inhibitor development, a structural perspective
Ian Hope et al.
RSC CHEMICAL BIOLOGY (2023)
Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations
Chuan Guo et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway
Deli Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma
Kai Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Small-molecule degraders of cyclin-dependent kinase protein: a review
Bin Yu et al.
FUTURE MEDICINAL CHEMISTRY (2022)
Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Deendyal Bhurta et al.
MEDICINAL RESEARCH REVIEWS (2022)
The Renaissance of Cyclin Dependent Kinase Inhibitors
Tobias Ettl et al.
CANCERS (2022)
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer
Qian Xie et al.
BREAST CARE (2022)
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
From Structure Modification to Drug Launch: A Systematic Reviewof the Ongoing Development of Cyclin-Dependent Kinase Inhibitorsfor Multiple Cancer Therapy
Zhenfeng Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Abemaciclib for malignant pleural mesothelioma
Valerio Nardone et al.
LANCET ONCOLOGY (2022)
Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
Weijiao Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
Elgene Lim et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer
Nathan W. Watson et al.
CANCER (2022)
Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future
Sonal M. Manohar
FUTURE MEDICINAL CHEMISTRY (2022)
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Chris Arter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease
Tammy Ladduwahetty et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Seth A. Wander et al.
ONCOLOGIST (2022)
A NOVEL CDK4/6 INHIBITOR WXJ-111, AGAINST BREAST CANCER THROUGH MEDIATED CELL-CYCLE ARREST AND APOPTOSIS
Jing Ji et al.
ACTA POLONIAE PHARMACEUTICA (2022)
A review on the role of cyclin dependent kinases in cancers
Soudeh Ghafouri-Fard et al.
CANCER CELL INTERNATIONAL (2022)
Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Mohd. Yousuf et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2022)
Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia
Kunming Qi et al.
LEUKEMIA RESEARCH (2022)
Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
Sen Sun et al.
PHARMACEUTICAL BIOLOGY (2022)
Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022)
Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors
Alexander Sokolsky et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase
Mingsong Shi et al.
ACS OMEGA (2022)
Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract
Fuchun Zeng et al.
IN VIVO (2022)
Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib
Mingsong Shi et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2022)
Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
Yuki Mitarai et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt et al.
BREAST CANCER RESEARCH (2022)
Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
Hideki Nawa et al.
CANCER REPORTS (2022)
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan et al.
ACTA PHARMACEUTICA SINICA B (2021)
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
Preclinical discovery and development of abemaciclib used to treat breast cancer
Matthew D. Wright et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
Ines H. Kaltheuner et al.
NATURE COMMUNICATIONS (2021)
Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors
Roberta Tesch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
Xiao-Jing Pang et al.
MOLECULES (2021)
ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution
Chuan Tian et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Generalized Born Implicit Solvent Models for Biomolecules
Alexey V. Onufriev et al.
ANNUAL REVIEW OF BIOPHYSICS, VOL 48 (2019)
Molecular Dynamics Investigations Suggest a Non-specific Recognition Strategy of 14-3-3σ Protein by Tweezer: Implication for the Inhibition Mechanism
Mingsong Shi et al.
FRONTIERS IN CHEMISTRY (2019)
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma
Sarah M. Bronner et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Ensemble Docking in Drug Discovery
Rommie E. Amaro et al.
BIOPHYSICAL JOURNAL (2018)
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
Andrew Fensome et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Parallelization of CPPTRAJ Enables Large Scale Analysis of Molecular Dynamics Trajectory Data
Daniel R. Roe et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2018)
Cell cycle proliferation decisions: the impact of single cell analyses
Jacob P. Matson et al.
FEBS JOURNAL (2017)
The opening/closure of the P-loop and hinge of BCR-ABL1 decodes the low/high bioactivities of dasatinib and axitinib
Jianyi Wang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2017)
The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
Jeffrey Small et al.
ONCOTARGET (2017)
CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
Juliann E. Kosovec et al.
ONCOTARGET (2017)
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Raquel Torres-Guzman et al.
ONCOTARGET (2017)
RhoA/Rho-Kinase in the Cardiovascular System
Hiroaki Shimokawa et al.
CIRCULATION RESEARCH (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Kinase hinge binding scaffolds and their hydrogen bond patterns
Li Xing et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Samuel Genheden et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Molecular Dynamics Simulations and Structural Network Analysis of c-Abl and c-Src Kinase Core Proteins: Capturing Allosteric Mechanisms and Communication Pathways from Residue Centrality
Amanda Tse et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Pairwise Decomposition of an MMGBSA Energy Function for Computational Protein Design
Thomas Gaillard et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2014)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Detailed conformation dynamics and activation process of wild type c-Abl and T3151 mutant
Li-Jun Yang et al.
JOURNAL OF MOLECULAR STRUCTURE (2014)
Signaling through cyclin D-dependent kinases
Y. J. Choi et al.
ONCOGENE (2014)
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
Young Shin Cho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6
Young Shin Cho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel potent pharmacological cyclin-dependent kinase inhibitors
Jozefa Wesierska-Gadek et al.
FUTURE MEDICINAL CHEMISTRY (2009)
Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes
M. Macaluso et al.
ONCOGENE (2006)
Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition
Heshu Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin
HS Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
An efficient hybrid explicit/implicit solvent method for biomolecular simulations
MS Lee et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)